Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012

Via Scoop.it – ALS Lou Gehrig’s Disease
Neuralstem, Inc. announces that President and CEO Richard Garr will present at the 14th Annual BIO CEO & Investor Conference 2012 in New York City on Monday, February 13, at 3:00 p.m. EST. Garr will present a business overview, and an update on the company’s ongoing clinical trials in both its cell therapy. Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA. The webcast will be available in real-time at http://www.veracast.com/webcasts/bio/ceoinvestor2012/43114242.cfm , and again beginning one hour after the conclusion of the live event, and archived for 90 days. The webcast link will also be posted on the Investor Center home page on Neuralstem’s website: http://www.neuralstem.com .
Via news.google.com